These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16783027)

  • 1. Statistical analysis of pathogenicity of somatic mutations in cancer.
    Greenman C; Wooster R; Futreal PA; Stratton MR; Easton DF
    Genetics; 2006 Aug; 173(4):2187-98. PubMed ID: 16783027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutations in human cancer: database reassessment and prospects for the next decade.
    Leroy B; Anderson M; Soussi T
    Hum Mutat; 2014 Jun; 35(6):672-88. PubMed ID: 24665023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the functional consequences of somatic missense mutations found in tumors.
    Carter H; Karchin R
    Methods Mol Biol; 2014; 1101():135-59. PubMed ID: 24233781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
    Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
    Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Likelihood models of somatic mutation and codon substitution in cancer genes.
    Yang Z; Ro S; Rannala B
    Genetics; 2003 Oct; 165(2):695-705. PubMed ID: 14573481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signs of positive selection of somatic mutations in human cancers detected by EST sequence analysis.
    Babenko VN; Basu MK; Kondrashov FA; Rogozin IB; Koonin EV
    BMC Cancer; 2006 Feb; 6():36. PubMed ID: 16469093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
    Pollock PM; Pearson JV; Hayward NK
    Genes Chromosomes Cancer; 1996 Feb; 15(2):77-88. PubMed ID: 8834170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring preferred amino acid mutations in cancer genes: Applications to identify potential drug targets.
    Anoosha P; Sakthivel R; Michael Gromiha M
    Biochim Biophys Acta; 2016 Feb; 1862(2):155-65. PubMed ID: 26581171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response.
    Deissler H; Kafka A; Schuster E; Sauer G; Kreienberg R; Zeillinger R
    Oncol Rep; 2004 Jun; 11(6):1281-6. PubMed ID: 15138567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current topics in mutations in the cancer genome].
    Iwaya T; Mimori K; Wakabayashi G
    Nihon Geka Gakkai Zasshi; 2012 Mar; 113(2):185-90. PubMed ID: 22582578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alport syndrome. Molecular genetic aspects.
    Hertz JM
    Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM).
    Carter H; Samayoa J; Hruban RH; Karchin R
    Cancer Biol Ther; 2010 Sep; 10(6):582-7. PubMed ID: 20581473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of coding and non-coding mutational hotspots in cancer genomes.
    Piraino SW; Furney SJ
    BMC Genomics; 2017 Jan; 18(1):17. PubMed ID: 28056774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic mutations in the BRCA1 gene in Chinese women with sporadic breast cancer.
    Zhang M; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Breast Cancer Res Treat; 2012 Feb; 132(1):335-40. PubMed ID: 22116506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.
    Petitjean A; Achatz MI; Borresen-Dale AL; Hainaut P; Olivier M
    Oncogene; 2007 Apr; 26(15):2157-65. PubMed ID: 17401424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants.
    Greenblatt MS; Beaudet JG; Gump JR; Godin KS; Trombley L; Koh J; Bond JP
    Oncogene; 2003 Feb; 22(8):1150-63. PubMed ID: 12606942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic mutations of the ERBB4 kinase domain in human cancers.
    Soung YH; Lee JW; Kim SY; Wang YP; Jo KH; Moon SW; Park WS; Nam SW; Lee JY; Yoo NJ; Lee SH
    Int J Cancer; 2006 Mar; 118(6):1426-9. PubMed ID: 16187281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay.
    Duddy PM; Hanby AM; Barnes DM; Camplejohn RS
    J Mol Diagn; 2000 Aug; 2(3):139-44. PubMed ID: 11229518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.